High Growth Tech Stocks Including ABL Bio To Watch

In This Article:

In the wake of recent tariff announcements by the Trump administration, global markets have experienced significant volatility, with small-cap stocks particularly hard-hit as evidenced by the Russell 2000 Index's sharp decline. Amid this backdrop of economic uncertainty and heightened trade tensions, investors are increasingly focused on identifying high-growth tech stocks that can navigate these challenging conditions; companies like ABL Bio offer intriguing opportunities due to their potential for innovation and resilience in a fluctuating market environment.

Top 10 High Growth Tech Companies Globally

Name

Revenue Growth

Earnings Growth

Growth Rating

Shanghai Baosight SoftwareLtd

21.43%

27.67%

★★★★★★

Inspur Digital Enterprise Technology

29.82%

29.69%

★★★★★★

eWeLLLtd

24.66%

25.31%

★★★★★★

Pharma Mar

24.24%

40.82%

★★★★★★

Seojin SystemLtd

31.68%

39.34%

★★★★★★

Yubico

20.88%

26.53%

★★★★★★

Ascelia Pharma

46.09%

66.93%

★★★★★★

CD Projekt

33.68%

36.76%

★★★★★★

Elliptic Laboratories

49.76%

88.21%

★★★★★★

JNTC

34.26%

86.00%

★★★★★★

Click here to see the full list of 766 stocks from our Global High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

ABL Bio

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc., with a market cap of ₩1.65 trillion, is a biotech research company dedicated to developing therapeutic drugs for immuno-oncology and neurodegenerative diseases.

Operations: The company generates revenue from its biotechnology segment, amounting to ₩33.40 billion. It focuses on developing therapeutic drugs targeting immuno-oncology and neurodegenerative diseases.

ABL Bio's recent licensing agreement with GSK highlights its innovative approach in tackling neurodegenerative diseases, leveraging its Grabody-B platform to enhance drug delivery across the blood-brain barrier—a significant advancement given the historical challenges in this therapy area. This deal not only brings an immediate financial boost with a £38.5 million upfront payment but also opens potential for up to £2.075 billion in milestone payments, reflecting high confidence in ABL Bio's technology. Additionally, ABL Bio's revenue is projected to grow at 22.4% annually, outpacing the broader KR market growth of 7.1%, positioning it favorably within the high-tech biotech sector despite current unprofitability and market volatility.

KOSDAQ:A298380 Earnings and Revenue Growth as at Apr 2025
KOSDAQ:A298380 Earnings and Revenue Growth as at Apr 2025

NHN

Simply Wall St Growth Rating: ★★★★☆☆

Overview: NHN Corporation is an IT company offering gaming, payment, entertainment, IT, and advertisement solutions both in South Korea and internationally, with a market cap of ₩610.15 billion.